Navigation Links
UT MD Anderson study finds link between statins and improved survival in inflammatory breast cancer
Date:12/6/2012

HOUSTON - Researchers from The University of Texas MD Anderson Cancer Center found statins, the commonly used drug to lower cholesterol, improved progression-free survival in patients with inflammatory breast cancer (IBC).

The retrospective study was presented today in a poster discussion at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium and follows a previously reported Danish study indicating there is some evidence to suggest the anti-inflammatory properties of statins could reduce the risk of breast cancer recurrence. Still, the overall effects of statins have not been examined in relation to IBC.

IBC is a rare type of breast cancer that develops quickly when malignant cells block lymph vessels in the skin and soft tissue. It accounts for only 1-5 percent of all invasive breast cancers, according to the American Cancer Society.

"We decided to take a different approach with the smaller population of inflammatory breast cancer patients and see if it's truly an inflammatory disease, whether or not there's some substantial impact of statin use in this population," said Naoto T. Ueno, M.D., Ph.D., professor in MD Anderson's Department of Breast Medical Oncology and executive director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic.

Ueno, the corresponding author, and his colleagues reviewed 724 patients diagnosed and treated for stage III inflammatory breast cancer at MD Anderson between 1995 and 2011. Patients with records indicating statin use at the time of diagnosis were compared to those who were not taking statins. In total, the stage III group contained 74 statin users and 650 non-users.

The primary end-point was progression-free survival (PFS), while secondary end-points measured overall survival (OS) and disease-specific survival (DSS).

Additionally, researchers compared the clinical outcomes of those in the statin group based on the type of statin, lipophilic (fat-soluble) or hydrophilic (water-soluble), an important distinction as differences in survival emerged throughout the trial. The authors note patients who used both drug categories, or patients missing information on their specific statin type, were excluded from the survival estimates.

Outcomes Show Improvement

Patients with no record of statin use had 1.76 years DFS, while patients who took lipophilic statins saw improved survival rates of 2.47 years. The greatest improvement in survival was noted in patients with past hydrophilic statin use at 4.88 years.

Increased survival rates also extended to the DSS end-point. Patients with no statin use measured a DSS of 4.52 years, while hydrophilic patients measured 5.10 years.

The authors note there is a trend in overall survival, however the OS end-point did not reach statistical significance.

"The previous Danish study looking at statins examined a much larger group of participants, around 10,000 and more. So we're talking about a much smaller set of inflammatory breast cancer patients and to see the significant improvement in survival gives us a new perspective on the use of statins," said Ueno.

While Ueno added the findings are encouraging, the study does have limitations. First, no data was available describing how long patients had been taking statins, or for what indication. Those who did use statins may represent a population with better access to health care, a more health-conscious lifestyle and a higher education level, according to the researchers.

"This is an existing drug that was not developed for cancer and while developing new agents is important, statins are currently in the market and may have a significant role in the treatment we provide," he said.

Additional Research Warranted

MD Anderson researchers are planning prospective randomized studies in IBC patients to better evaluate the potential survival benefits of statins. Further studies also hope to identify what subset of populations would be best suited for statin use. Ueno said there is an important convenience factor involved, as participants can take statins anywhere and require only occasional follow-up.


'/>"/>
Contact: William Fitzgerald
wbfitzgerald@mdanderson.org
713-792-9518
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. UT MD Anderson study finds cancer related pain often undertreated
2. University of Houston Graduate College of Social Work announces partnership with MD Anderson
3. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
4. UT MD Anderson study finds link between depressive symptoms and cancer survival
5. UT MD Anderson Cancer Center launches unprecedented Moon Shots Program
6. Study Suggests Vaccine May Help Kids With Brain Cancer
7. Study reveals how cancer drug causes diabetic-like state
8. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
9. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. No Added Cancer Risk From Hip Replacement Materials: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT MD Anderson study finds link between statins and improved survival in inflammatory breast cancer
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... Individuals ... protective measures, such as drinking more water or limiting their exposure to the sun, ... California health and beauty group Beverly Hills Physicians (BHP) notes that, while preventive measures ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
(Date:12/6/2016)... , ... December 06, 2016 , ... Why does the ... Proietto, MB BS, PhD, FRACP, includes a fresh look into the cause of obesity ... evidence-based strategy providing readers with the knowledge needed to lead a healthy life. Proietto ...
(Date:12/6/2016)... ... December 06, 2016 , ... The NALA, a boutique marketing agency, is ... Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families ... To assist TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in ...
(Date:12/6/2016)... ... December 06, 2016 , ... The V ... announce its Not a Moment to Lose fundraising campaign. As the V Foundation’s ... to declaring victory over cancer. The campaign aims to raise $200 million by ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)...  Nearly 30 million people in the ... diabetes. 1 However, nearly 40% of diabetes patients ... and significant glucose variability. 2 These patients are at ... If left untreated, hyperglycemia can lead to cardiovascular disease, ... 3 As part of Diabetes Awareness ...
(Date:12/6/2016)... Dec. 6, 2016  Arcturus Therapeutics, Inc. ("Arcturus" ... announced today that it entered into collaboration with ... for the treatment of NASH and other gastrointestinal ... platform LUNAR™ and UNA Oligomer chemistry. The financial ... long-standing commitment to and expertise in GI disorders, ...
(Date:12/6/2016)... 2016 Breast Pump Market size is estimated ... by Global Market Insights, Inc. Continue Reading ... ... , , ... women employment rates and rising consumer awareness regarding importance of breast feeding will ...
Breaking Medicine Technology: